Ignite Creation Date:
2024-05-06 @ 4:52 PM
Last Modification Date:
2024-10-26 @ 2:17 PM
Study NCT ID:
NCT05117060
Status:
COMPLETED
Last Update Posted:
2024-06-04
First Post:
2021-11-08
Brief Title:
Efficacy and Safety of LEO 152020 Tablets for the Treatment of Adults With Moderate to Severe Atopic Dermatitis
Sponsor:
JW Pharmaceutical
Organization:
JW Pharmaceutical
Study Overview
Official Title:
A Phase 2 Trial to Evaluate the Efficacy and Safety of Orally Administered LEO 152020 Tablets Compared With Placebo Tablets for up to 16 Weeks of Treatment in Adults With Moderate to Severe Atopic Dermatitis
Status:
COMPLETED
Status Verified Date:
2024-05
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an up to 22-week clinical study in adult participants with moderate to severe atopic dermatitis AD
The purpose of the study is to test a new tablet LEO 152020 to see if it improves AD and what the side effects are when compared with a placebo tablet with no medical ingredient
During the study there will be a 16-week treatment period during which the participants will be asked to take the tablets The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD The participants will also be asked to answer questions about their AD symptoms itch sleep and quality of life
The purpose of the study is to test a new tablet LEO 152020 to see if it improves AD and what the side effects are when compared with a placebo tablet with no medical ingredient
During the study there will be a 16-week treatment period during which the participants will be asked to take the tablets The participants will regularly visit the clinic for tests and the study doctor will evaluate their AD The participants will also be asked to answer questions about their AD symptoms itch sleep and quality of life
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| U1111-1281-1895 | OTHER | World Health Organization WHO | None |
| 2020-004561-39 | EUDRACT_NUMBER | None | None |